Array
(
[id] => 570
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/570.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients with an indication for statins, it should be considered to initiate statins peri-operatively.（Evidence: Level C，Recommendation:Class IIa）
[laiyuan] => 对于有他汀类药物适应症的患者，应考虑围手术期使用他汀类药物。（证据级别：Level C ；推荐强度：Class IIa）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于有他汀类药物适应症的患者，应考虑围手术期使用他汀类药物。（证据级别：Level C ；推荐强度：Class IIa）
In patients with an indication for statins, it should be considered to initiate statins peri-operatively.（Evidence: Level C，Recommendation:Class IIa）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 571
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/571.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => Pre-operative initiation of beta-blockers in advance of high-risk NCS may be considered in patients who have two or more clinical risk factors, in order to reduce the incidence of
peri-operative myocardial infarction.（Evidence: Level A，Recommendation:Class IIb）
[laiyuan] => 对于有两个或两个以上临床危险因素的患者，可考虑在高危NCS术前开始使用β-受体阻滞剂，以降低围手术期心肌梗死的发生率。（证据级别：Level A；推荐强度：Class IIb）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于有两个或两个以上临床危险因素的患者，可考虑在高危NCS术前开始使用β-受体阻滞剂，以降低围手术期心肌梗死的发生率。（证据级别：Level A；推荐强度：Class IIb）
Pre-operative initiation of beta-blockers in advance of high-risk NCS may be considered in patients who have two or more clinical risk factors, in order to reduce the incidence of
peri-operative myocardial infarction.（Evidence: Level A，Recommendation:Class IIb）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 572
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/572.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => Pre-operative initiation of beta-blocker in advance of NCS may be considered in patients who have known CAD or myocardial ischaemia.（Evidence: Level B，Recommendation:Class IIb）
[laiyuan] => 对于已知冠心病或心肌缺血的患者，可考虑在NCS术前使用β-受体阻滞剂。（证据级别：Level B ；推荐强度：Class II b）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于已知冠心病或心肌缺血的患者，可考虑在NCS术前使用β-受体阻滞剂。（证据级别：Level B ；推荐强度：Class II b）
Pre-operative initiation of beta-blocker in advance of NCS may be considered in patients who have known CAD or myocardial ischaemia.（Evidence: Level B，Recommendation:Class IIb）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 573
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/573.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => Routine initiation of beta-blocker peri-operatively is not recommended.(Evidence: Level A，Recommendation: ClassⅢ)
[laiyuan] => 不推荐围手术期常规应用β-受体阻滞剂。（证据级别：Level A ；推荐强度：Class Ⅲ）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
不推荐围手术期常规应用β-受体阻滞剂。（证据级别：Level A ；推荐强度：Class Ⅲ）
Routine initiation of beta-blocker peri-operatively is not recommended.(Evidence: Level A，Recommendation: ClassⅢ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 574
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/574.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication.（Evidence: Level B，Recommendation:Class Ⅰ）
[laiyuan] => 推荐目前正在接受β-受体阻滞剂物治疗的患者围手术期继续使用。（证据级别：Level B ；推荐强度：Class Ⅰ）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
推荐目前正在接受β-受体阻滞剂物治疗的患者围手术期继续使用。（证据级别：Level B ；推荐强度：Class Ⅰ）
Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication.（Evidence: Level B，Recommendation:Class Ⅰ）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 575
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/575.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients already on statins, it is recommended
to continue statins during the peri-operative
period.（Evidence: Level B，Recommendation:Class I）
[laiyuan] => 对于已经服用他汀类药物的患者，建议在围手术期继续服用他汀类药物。（证据级别：Level B；推荐强度：Class I）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于已经服用他汀类药物的患者，建议在围手术期继续服用他汀类药物。（证据级别：Level B；推荐强度：Class I）
In patients already on statins, it is recommended
to continue statins during the peri-operative
period.（Evidence: Level B，Recommendation:Class I）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 576
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/576.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients with stable HF, peri-operative continuation of RAAS inhibitors may be considered.（Evidence: Level C，Recommendation:Class IIb）
[laiyuan] => 对于稳定的心衰患者，可以考虑围手术期继续使用RAAS抑制剂。（证据级别：Level C ；推荐强度：Class II b）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于稳定的心衰患者，可以考虑围手术期继续使用RAAS抑制剂。（证据级别：Level C ；推荐强度：Class II b）
In patients with stable HF, peri-operative continuation of RAAS inhibitors may be considered.（Evidence: Level C，Recommendation:Class IIb）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 577
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/577.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients without HF, withholding RAAS inhibitors on the day of NCS should be considered to prevent peri-operative hypotension.（Evidence: Level B，Recommendation:Class II a）
[laiyuan] => 对于无心衰的患者，应考虑在NCS当天停用RAAS抑制剂以预防围手术期低血压。（证据级别：Level B ；推荐强度：Class II a）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于无心衰的患者，应考虑在NCS当天停用RAAS抑制剂以预防围手术期低血压。（证据级别：Level B ；推荐强度：Class II a）
In patients without HF, withholding RAAS inhibitors on the day of NCS should be considered to prevent peri-operative hypotension.（Evidence: Level B，Recommendation:Class II a）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 578
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/578.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => For patients on diuretics to treat hypertension,transient discontinuation of diuretics on the day of NCS should be considered.（Evidence: Level B，Recommendation:Class II a）
[laiyuan] => 对于服用利尿剂治疗高血压的患者，应考虑在NCS当天短暂停用利尿剂。（证据级别：Level B ；推荐强度：Class II a）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于服用利尿剂治疗高血压的患者，应考虑在NCS当天短暂停用利尿剂。（证据级别：Level B ；推荐强度：Class II a）
For patients on diuretics to treat hypertension,transient discontinuation of diuretics on the day of NCS should be considered.（Evidence: Level B，Recommendation:Class II a）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 579
[catid] => 192
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/579.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:03
[updatetime] => 2024-01-11 15:13:03
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS.（Evidence: Level C，Recommendation:Class II a）
[laiyuan] => 应考虑在中危和高危NCS之前中断钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂治疗至少3天。（证据级别：Level C ；推荐强度：Class II a）
[znzldj] => A
[_inputtime] => 1704957183
[_updatetime] => 1704957183
[_nrjc] =>
[_nrsh] =>
)
推荐意见
应考虑在中危和高危NCS之前中断钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂治疗至少3天。（证据级别：Level C ；推荐强度：Class II a）
It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS.（Evidence: Level C，Recommendation:Class II a）
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
